Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Amphastar Pharmaceuticals, Inc. (AMPH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value of $11.16 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue · last filed 2026-08-06
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $11.16M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $8.80M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $33.37M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value $33.33M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value |
|---|---|
| 2026-06-30 | $11.16M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $8.80M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $33.37M 10-K · filed 2026-02-26 |
| 2025-09-30 | $33.33M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $20.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $46.35M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $95.07M 10-K · filed 2025-03-03 |
| 2024-09-30 | $167.35M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $119.37M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $150.34M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $322.20M 10-K · filed 2024-02-29 |
| 2023-09-30 | $205.03M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $298.51M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $154.40M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $85.92M 10-K · filed 2023-03-01 |
| 2022-09-30 | $87.24M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $135.97M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $150.96M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $63.21M 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |